Clinical trial

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

NCT01254864

Study summary

ClinicalTrials.gov

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Abiraterone Acetate Normalized identity: abiraterone acetate View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Prednisone Normalized identity: prednisone View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Sunitinib Normalized identity: sunitinib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Dasatinib Normalized identity: dasatinib View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-03-16

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

Abiraterone AcetateDRUG · verified · RxNorm: abiraterone acetate

PrednisoneDRUG · verified · RxNorm: prednisone

SunitinibDRUG · verified · RxNorm: sunitinib

DasatinibDRUG · verified · RxNorm: dasatinib

Sponsors & collaborators

M.D. Anderson Cancer Centerlead sponsor

Bristol-Myers Squibbcollaborator

Janssen Scientific Affairs, LLCcollaborator

Pfizercollaborator

Mapped research locations

HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01254864 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.